ProPhase Labs, Inc. reports developments across a diversified life sciences, diagnostics, genomics and consumer health portfolio. Recurring company updates include the BE-Smart™ esophageal cancer risk stratification test, Crown Medical Collections activity tied to legacy COVID-19 testing receivables, and Nebula Genomics, including the DNA Complete direct-to-consumer whole genome sequencing platform.
PRPH news also covers capital-structure actions, convertible debt conversions, financing discussions, operating and financial results, governance matters, and the company’s trading-status transition from Nasdaq and the Pink Sheets to the OTC market. These updates frame ProPhase as an OTC-traded healthcare issuer with diagnostic, genomic data, consumer health, and receivables-related assets.
ProPhase Labs, Inc. (NASDAQ: PRPH) announced an at-the-market equity offering sales agreement with A.G.P./Alliance Global Partners, enabling the company to sell shares through various methods on the Nasdaq. The proceeds from this offering will support working capital, product development, acquisitions, and general corporate purposes. ProPhase has approximately $20 million in working capital, enhanced by a recent debt financing. CEO Ted Karkus emphasized the flexibility gained from the ATM facility to access capital for strategic transactions and opportunities.
ProPhase Labs, Inc. (NASDAQ: PRPH) has successfully closed a $10 million unsecured debt financing through two promissory notes. Each note matures in three years and accrues 10% annual interest, payable quarterly. Lenders can convert up to $3 million of the notes into common stock at a price of $3.00 per share after 13 months. The funds will be allocated for working capital, product development, and potential acquisitions. The CEO emphasized existing working capital of about $10 million will enhance business opportunities.
ProPhase Labs, Inc. reported net sales of $3.6 million for Q2 2020, an increase from $1.7 million in Q2 2019. The company achieved net income of $70,000 ($0.01 per share), reversing a net loss of $1.2 million ($0.11 per share) year-over-year. For the first half of 2020, net sales totaled $5.5 million, up from $4.0 million in the prior year, with a reduced net loss of $0.7 million compared to $2.3 million. This improvement stemmed from a rise in third-party orders and reductions in costs across various expense categories.
ProPhase Labs, Inc. (NASDAQ: PRPH) reported Q1 2020 net sales of $1.9 million, down from $2.3 million in Q1 2019. The net loss narrowed to $809,000 or ($0.07) per share compared to a net loss of $1.0 million or ($0.09) per share the previous year. Contributing factors included a $430,000 decline in sales due to reduced customer demand, offset by decreased costs in administration ($206,000), marketing ($96,000), and R&D ($35,000). Additionally, the Company released $4.8 million from escrow following a resolved claim with Mylan on May 4, 2020.